Buy Cipla; target of Rs 750: Edelweiss

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Edelweiss' report on Cipla

"Cipla’s (CIPL) Q4FY15 EBITDA margin (16.4%) was below estimate with consolidation of acquired entities and bunching up of R&D diluting the leverage from strong growth. Exports growth and improvement in gross margin are key positives and the crux of our thesis. We believe FY16 guidance (15% growth, 150bps margin expansion) is conservative as its initiatives / pipeline start delivering. Operating leverage and mix will drive 42% EPS CAGR (highest in the sector) and multiple triggers will support premium valuations. Initial success with Advair MDI approvals (7 countries in EU, M/S gains) encourages us to add INR100/share of risk adjusted NPV for respiratory franchise to our target price. Our revised target price is INR750 (INR770 earlier) — base business at INR650 (17x FY17E) plus respiratory franchise NPV of INR100. Maintain ‘BUY’ and CIPL as our top large-cap conviction pick."

"We believe CIPL’s guidance is conservative given several recent initiatives: a) EU inhalers ramp up – already launched in 7 countries;  more launches across EU (including the UK) to follow; b) US sales can grow strongly – niche launches (Pulmicort) can accelerate growth; c) Nexium (Teva partner USD2bn market) will continue to benefit CIPL with limited competition in sight; d) South Africa - Teva deal could accelerate growth; e) Sovaldi launch in India and EMs; f) better realisations from newly established front ends. We cut our estimates to factor a muted Q4FY15, but forecast EPS to double over FY15-17 as operating leverage and mix benefits kick in. Valuations at 18.5x FY17E (adjusted for NPV) are attractive. We maintain ‘BUY/SO’ ", says Edelweiss research report.

For all recommendations, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

Read More